WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H574937
CAS#: WZ4002 (HBr)
Description: WZ4002 hydrobromide is used in of pteridin-7(8H)one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
Hodoodo Cat#: H574937
Name: WZ4002 hydrobromide
CAS#: WZ4002 (HBr)
Chemical Formula: C25H28BrClN6O3
Exact Mass: 574.11
Molecular Weight: 575.890
Elemental Analysis: C, 52.14; H, 4.90; Br, 13.87; Cl, 6.16; N, 14.59; O, 8.33
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 1213269-23-8 WZ4002 (HBr) WZ4002-hydroxy
Synonym: WZ4002 hydrobromide; WZ4002 HBr
IUPAC/Chemical Name: N-[3-[[5-Chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide Hydrobromide
InChi Key: UXXWSHAAGQQVJT-UHFFFAOYSA-N
InChi Code: InChI=1S/C25H27ClN6O3.BrH/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32;/h4-9,14-16H,1,10-13H2,2-3H3,(H,28,33)(H,27,29,30);1H
SMILES Code: C=CC(NC1=CC=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3OC)=NC=C2Cl)=C1)=O.[H]Br
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 575.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1. Romu AA, Lei Z, Zhou B, Chen ZS, Korlipara V. Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors. Bioorg Med Chem Lett. 2017 Nov 1;27(21):4832-4837. doi: 10.1016/j.bmcl.2017.09.048. Epub 2017 Sep 25. PMID: 28974338.
2. Lu X, Yu L, Zhang Z, Ren X, Smaill JB, Ding K. Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry. Med Res Rev. 2018 Sep;38(5):1550-1581. doi: 10.1002/med.21488. Epub 2018 Jan 26. PMID: 29377179.
